American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review

Matthew M. Harkenrider, Alec M. Block, Kaled M. Alektiar, David K. Gaffney, Ellen Jones, Ann Klopp, Akila N. Viswanathan, William Small

Research output: Research - peer-reviewReview article

  • 3 Citations

Abstract

This article aims to review the risk stratification of endometrial cancer, treatment rationale, outcomes, treatment planning, and treatment recommendations of vaginal brachytherapy (VBT) in the postoperative management of endometrial cancer patients. The authors performed a thorough review of the literature and reference pertinent articles pertaining to the aims of this review. Adjuvant VBT for early-stage endometrial cancer patients results in very low rates of vaginal recurrence (0–3.1%) with low rates of late toxicity which are primarily vaginal in nature. Post-Operative Radiation Therapy in Endometrial Cancer 2 (PORTEC-2) supports that VBT results in noninferior rates of vaginal recurrence compared to external beam radiotherapy for the treatment of high-intermediate risk patients. VBT as a boost after external beam radiotherapy, in combination with chemotherapy, and for high-risk histologies have shown excellent results as well though randomized data do not exist supporting VBT boost. There are many different applicators, dose-fractionation schedules, and treatment planning techniques which all result in favorable clinical outcomes and low rates of toxicity. Recommendations have been published by the American Brachytherapy Society and the American Society of Radiation Oncology to help guide practitioners in the use of VBT. Data support that patients and physicians prefer joint decision making regarding the use of VBT, and patients often desire additional treatment for a marginal benefit in risk of recurrence. Discussions regarding adjuvant therapy for endometrial cancer are best performed in a multidisciplinary setting, and patients should be counseled properly regarding the risks and benefits of adjuvant therapy.

LanguageEnglish (US)
Pages95-108
Number of pages14
JournalBrachytherapy
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Brachytherapy
Endometrial Neoplasms
Therapeutics
Radiotherapy
Recurrence
Planning Techniques
Dose Fractionation
Radiation Oncology
Combination Drug Therapy
Decision Making
Histology
Appointments and Schedules
Physicians

Keywords

  • Endometrial cancer
  • Gynecologic brachytherapy
  • Vaginal brachytherapy
  • Vaginal cuff
  • Vaginal cuff brachytherapy
  • Vaginal cylinder

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Harkenrider, M. M., Block, A. M., Alektiar, K. M., Gaffney, D. K., Jones, E., Klopp, A., ... Small, W. (2017). American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. Brachytherapy, 16(1), 95-108. DOI: 10.1016/j.brachy.2016.04.005

American Brachytherapy Task Group Report : Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. / Harkenrider, Matthew M.; Block, Alec M.; Alektiar, Kaled M.; Gaffney, David K.; Jones, Ellen; Klopp, Ann; Viswanathan, Akila N.; Small, William.

In: Brachytherapy, Vol. 16, No. 1, 01.01.2017, p. 95-108.

Research output: Research - peer-reviewReview article

Harkenrider, MM, Block, AM, Alektiar, KM, Gaffney, DK, Jones, E, Klopp, A, Viswanathan, AN & Small, W 2017, 'American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review' Brachytherapy, vol 16, no. 1, pp. 95-108. DOI: 10.1016/j.brachy.2016.04.005
Harkenrider, Matthew M. ; Block, Alec M. ; Alektiar, Kaled M. ; Gaffney, David K. ; Jones, Ellen ; Klopp, Ann ; Viswanathan, Akila N. ; Small, William. / American Brachytherapy Task Group Report : Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. In: Brachytherapy. 2017 ; Vol. 16, No. 1. pp. 95-108
@article{fc55cf02a408490bbfbde192c9f04c93,
title = "American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review",
abstract = "This article aims to review the risk stratification of endometrial cancer, treatment rationale, outcomes, treatment planning, and treatment recommendations of vaginal brachytherapy (VBT) in the postoperative management of endometrial cancer patients. The authors performed a thorough review of the literature and reference pertinent articles pertaining to the aims of this review. Adjuvant VBT for early-stage endometrial cancer patients results in very low rates of vaginal recurrence (0–3.1%) with low rates of late toxicity which are primarily vaginal in nature. Post-Operative Radiation Therapy in Endometrial Cancer 2 (PORTEC-2) supports that VBT results in noninferior rates of vaginal recurrence compared to external beam radiotherapy for the treatment of high-intermediate risk patients. VBT as a boost after external beam radiotherapy, in combination with chemotherapy, and for high-risk histologies have shown excellent results as well though randomized data do not exist supporting VBT boost. There are many different applicators, dose-fractionation schedules, and treatment planning techniques which all result in favorable clinical outcomes and low rates of toxicity. Recommendations have been published by the American Brachytherapy Society and the American Society of Radiation Oncology to help guide practitioners in the use of VBT. Data support that patients and physicians prefer joint decision making regarding the use of VBT, and patients often desire additional treatment for a marginal benefit in risk of recurrence. Discussions regarding adjuvant therapy for endometrial cancer are best performed in a multidisciplinary setting, and patients should be counseled properly regarding the risks and benefits of adjuvant therapy.",
keywords = "Endometrial cancer, Gynecologic brachytherapy, Vaginal brachytherapy, Vaginal cuff, Vaginal cuff brachytherapy, Vaginal cylinder",
author = "Harkenrider, {Matthew M.} and Block, {Alec M.} and Alektiar, {Kaled M.} and Gaffney, {David K.} and Ellen Jones and Ann Klopp and Viswanathan, {Akila N.} and William Small",
year = "2017",
month = "1",
doi = "10.1016/j.brachy.2016.04.005",
volume = "16",
pages = "95--108",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - American Brachytherapy Task Group Report

T2 - Brachytherapy

AU - Harkenrider,Matthew M.

AU - Block,Alec M.

AU - Alektiar,Kaled M.

AU - Gaffney,David K.

AU - Jones,Ellen

AU - Klopp,Ann

AU - Viswanathan,Akila N.

AU - Small,William

PY - 2017/1/1

Y1 - 2017/1/1

N2 - This article aims to review the risk stratification of endometrial cancer, treatment rationale, outcomes, treatment planning, and treatment recommendations of vaginal brachytherapy (VBT) in the postoperative management of endometrial cancer patients. The authors performed a thorough review of the literature and reference pertinent articles pertaining to the aims of this review. Adjuvant VBT for early-stage endometrial cancer patients results in very low rates of vaginal recurrence (0–3.1%) with low rates of late toxicity which are primarily vaginal in nature. Post-Operative Radiation Therapy in Endometrial Cancer 2 (PORTEC-2) supports that VBT results in noninferior rates of vaginal recurrence compared to external beam radiotherapy for the treatment of high-intermediate risk patients. VBT as a boost after external beam radiotherapy, in combination with chemotherapy, and for high-risk histologies have shown excellent results as well though randomized data do not exist supporting VBT boost. There are many different applicators, dose-fractionation schedules, and treatment planning techniques which all result in favorable clinical outcomes and low rates of toxicity. Recommendations have been published by the American Brachytherapy Society and the American Society of Radiation Oncology to help guide practitioners in the use of VBT. Data support that patients and physicians prefer joint decision making regarding the use of VBT, and patients often desire additional treatment for a marginal benefit in risk of recurrence. Discussions regarding adjuvant therapy for endometrial cancer are best performed in a multidisciplinary setting, and patients should be counseled properly regarding the risks and benefits of adjuvant therapy.

AB - This article aims to review the risk stratification of endometrial cancer, treatment rationale, outcomes, treatment planning, and treatment recommendations of vaginal brachytherapy (VBT) in the postoperative management of endometrial cancer patients. The authors performed a thorough review of the literature and reference pertinent articles pertaining to the aims of this review. Adjuvant VBT for early-stage endometrial cancer patients results in very low rates of vaginal recurrence (0–3.1%) with low rates of late toxicity which are primarily vaginal in nature. Post-Operative Radiation Therapy in Endometrial Cancer 2 (PORTEC-2) supports that VBT results in noninferior rates of vaginal recurrence compared to external beam radiotherapy for the treatment of high-intermediate risk patients. VBT as a boost after external beam radiotherapy, in combination with chemotherapy, and for high-risk histologies have shown excellent results as well though randomized data do not exist supporting VBT boost. There are many different applicators, dose-fractionation schedules, and treatment planning techniques which all result in favorable clinical outcomes and low rates of toxicity. Recommendations have been published by the American Brachytherapy Society and the American Society of Radiation Oncology to help guide practitioners in the use of VBT. Data support that patients and physicians prefer joint decision making regarding the use of VBT, and patients often desire additional treatment for a marginal benefit in risk of recurrence. Discussions regarding adjuvant therapy for endometrial cancer are best performed in a multidisciplinary setting, and patients should be counseled properly regarding the risks and benefits of adjuvant therapy.

KW - Endometrial cancer

KW - Gynecologic brachytherapy

KW - Vaginal brachytherapy

KW - Vaginal cuff

KW - Vaginal cuff brachytherapy

KW - Vaginal cylinder

UR - http://www.scopus.com/inward/record.url?scp=84973571953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973571953&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2016.04.005

DO - 10.1016/j.brachy.2016.04.005

M3 - Review article

VL - 16

SP - 95

EP - 108

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 1

ER -